Skip to main content

NASDAQ:PULM - Pulmatrix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 459.35 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.89
▲ +0.02 (2.29%)
1 month | 3 months | 12 months
Get New Pulmatrix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PULM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PULM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▲ +459.35% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Pulmatrix in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 459.35% upside from the last price of $0.89.

Buy

The current consensus among 1 polled investment analysts is to buy stock in Pulmatrix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021HC WainwrightLower Price TargetBuy$10.00 ➝ $5.00N/A
i
4/13/2021HC WainwrightLower Price TargetBuy$10.00 ➝ $5.00High
i
9/24/2020HC WainwrightReiterated RatingBuy$10.00Medium
i
11/10/2019HC WainwrightReiterated RatingBuy$10.00Medium
i
4/16/2019HC WainwrightReiterated RatingBuyMedium
i
Rating by A. Fein at HC Wainwright
11/19/2018HC WainwrightReiterated RatingBuyHigh
i
3/16/2018HC WainwrightLower Price TargetBuy$30.00Medium
i
Rating by A. Fein at HC Wainwright
2/9/2018HC WainwrightInitiated CoverageBuy ➝ Buy$50.00High
i
Rating by A. Fein at HC Wainwright
9/27/2017Dawson JamesReiterated RatingBuyMedium
i
Rating by R. Wasserman at Dawson James
(Data available from 5/9/2016 forward)
Pulmatrix logo
Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $0.89
$0.86
$0.91

50 Day Range

MA: $1.18
$0.88
$1.48

52 Week Range

Now: $0.89
$0.86
$3.04

Volume

491,497 shs

Average Volume

2,241,172 shs

Market Capitalization

$50.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Pulmatrix?

The following equities research analysts have issued reports on Pulmatrix in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for PULM.

What is the current price target for Pulmatrix?

1 Wall Street analysts have set twelve-month price targets for Pulmatrix in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 459.3%. HC Wainwright has the highest price target set, predicting PULM will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Pulmatrix in the next year.
View the latest price targets for PULM.

What is the current consensus analyst rating for Pulmatrix?

Pulmatrix currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PULM will outperform the market and that investors should add to their positions of Pulmatrix.
View the latest ratings for PULM.

What other companies compete with Pulmatrix?

How do I contact Pulmatrix's investor relations team?

Pulmatrix's physical mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company's listed phone number is 781-357-2333 and its investor relations email address is [email protected] The official website for Pulmatrix is www.pulmatrix.com.